Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm Encourages Grail, Inc. (GRAL) Shareholders To Inquire About Securities Fraud Class Action

LOS ANGELES--(BUSINESS WIRE)--Glancy Prongay Wolke & Rotter LLP, a leading national shareholder rights law firm, announces that a securities fraud class action lawsuit has been filed on behalf of investors who purchased or otherwise acquired Grail, Inc. (“Grail” or the “Company”) (NASDAQ: GRAL) common stock between May 13, 2025 and February 19, 2026, inclusive (the “Class Period”). Grail investors have until August 4, 2026 to file a lead plaintiff motion.

IF YOU SUFFERED A LOSS ON YOUR GRAIL, INC. (GRAL) INVESTMENTS, CLICK HERE TO INQUIRE ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS UNDER THE FEDERAL SECURITIES LAWS

What Happened?

On February 19, 2026, Grail announced that the “primary endpoint of statistically significant Stage III-IV [cancer] reduction was not observed” in its NHS-Galleri Trial due, in part, to “probably need[ing] a longer follow-up time to be able to [compare the study arms] adequately.”

On this news, Grail’s stock price fell $51.32, or 50.5%, to close at $50.21 per share on February 20, 2026, thereby injuring investors.

What Is The Lawsuit About?

The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) the confidence management provided in light of the “Positive Top-Line Results” from the trial’s first screening round and the Pathfinder studies was misplaced and ignored potential trendlines in unreleased topline data and other information learned since the inception of the study that suggested three years would be less sufficient than previously thought to demonstrate the achievability of the primary endpoint; and (2) as a result, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.

If you purchased or otherwise acquired Grail common stock during the Class Period, you may move the Court no later than August 4, 2026 to request appointment as lead plaintiff in this putative class action lawsuit.

Contact Us To Participate or Learn More:

If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:

Charles Linehan, Esq.,
Glancy Prongay Wolke & Rotter LLP,
1925 Century Park East, Suite 2100,
Los Angeles California 90067
Email: [e-mail]
Telephone: [phone],
Toll-Free: 888-773-9224
Visit our website at www.glancylaw.com.
Follow us for updates on LinkedIn, Twitter, or Facebook.

If you inquire by email, please include your mailing address, telephone number and number of shares purchased.

To be a member of the Class you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the Class.

This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.